The U.S. Food and Drug Administration approved Roseland, N.J.-based Intervet's Resflor Gold (florfenicol and flunixin meglumine) for the treatment of bovine respiratory disease in beef and non-lactating dairy cattle.
Effective Jan. 11, 2010, the final rule made by the FDA’s Department of Health and Human Services approved Resflor Gold (florfenicol and flunixin meglumine), a combination injectable solution. The drug provides for treatment of BRD associated with Mannheima haemolytica, Pasteurella multocida, and Histophilus somni, as well as control of BRD-associated pyrexia in beef and non-lactating dairy cattle.
Under federal law, the drug is restricted for use by or on the order of a licensed veterinarian. In addition, animals intended for human consumption must not be slaughtered within 38 days of treatment.
The FDA also approved a label change for Woburn, Mass.-based Anika Therapeutics Inc.’s Hyaluronate sodium injectable solution, revising a human food safety warning on the product for the treatment of joint dysfunction in horses, which states, “Do not use in horses intended for human consumption.”
In related news, Elanco Animal Health, A Division of Eli Lilly & Co. of Indianapolis, Ind., got FDA approval for ractopamine hydrochloride Type C to be used for medicated feeds as a top dress to cattle fed in confinement for slaughter.